What's driving Aurinia Pharmaceuticals (AUPH)

Compiled from the engine's research, source claims and public filings in this dossier. Each has its own data date, listed below.

Research summary

Aurinia Voclosporin Generic Exclusivity Durability

Why it matters now

Longer protection from U.S. generic voclosporin competition preserves Aurinia's branded voclosporin revenue opportunity.

Next checkpoint

AUPH earnings (expected 2026-11-03)

This checkpoint sits on a shared driver. The engine does not explain how it carries over to AUPH, so treat it as context, not a verified checkpoint for this company.

What would break the thesis

A defined contingency permits Teva's earlier launch, or a ruling or settlement involving another challenger enables earlier generic entry.

Research drivers

Aurinia Voclosporin Generic Exclusivity Durability
Bullish · Active · Updated 2026-08-20
Teva's settlement defers generic entry until no earlier than December 7, 2036, while Teva stipulates that the relevant Aurinia patents are valid, enforceable, and infringed.

Source claims

This dossier has no related claim that comes with text, a source label and a valid date.

Related sectors

Biotech

Filed holders

This dossier has no filed holders to show. That does not mean no institution holds it.